Evaluation of acellular pertussis vaccine: comparisons among different strains of mice

References

• Kilgore PE, Salim AM, Zervos MJ, et al. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449-486. DOI:10.1128/CMR.00083-15
   PubMed Web of Science ®Google Scholar
• van der Zee A, Schellekens JF, Mooi FR. Laboratory diagnosis of pertussis. Clin Microbiol Rev 2015;28(4):1005–1026. DOI:10.1128/CMR.00031-15
   PubMed Web of Science ®Google Scholar
• Lefrancq N, Bouchez V, Fernandes N, et al. Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis. Sci Transl Med. 2022;14(642):eabn3253. DOI:10.1126/scitranslmed.abn3253
   PubMed Web of Science ®Google Scholar
• Boulet SL, Chamberlain AT, Biswas HH, et al. Trends in infant pertussis hospitalizations in the United States, 2009-2017. JAMA. 2019;322(21):2134–2136. DOI:10.1001/jama.2019.15577
   PubMed Web of Science ®Google Scholar
• Domenech de Celles M, Magpantay FMG, King AA, et al. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci Transl Med. 2018;10(434).
   Web of Science ®Google Scholar
• Harmon GE. Seasonal incidence of whooping cough in the United States. Am J Public Health Nations Health. 1932;22(8):831–839. DOI:10.2105/AJPH.22.8.831
   PubMedGoogle Scholar
• Wood N, Nolan T, Marshall H, et al. Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr. 2018;172(11):1045–1052. DOI:10.1001/jamapediatrics.2018.2349
   PubMed Web of Science ®Google Scholar
• Trs Annex P, Trs AT. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
   Google Scholar
• Commission CP. Pharmacopoeia of the People’s Republic of China. People’s Medical Publishing House; 2015.
   Google Scholar
• Kyokai NK. The Japanese pharmacopoeia; 2006.
   Google Scholar
• Korea. Korean pharmacopoeia. 10.0 ed. Korean Pharmacopoeia; 2012.
   Google Scholar
• Europe. European Pharmacopoeia. 10.0 ed. 2019.
   Google Scholar
• Dorji D, Graham RM, Singh AK, et al. Immunogenicity and protective potential of Bordetella pertussis biofilm and its associated antigens in a murine model. Cell Immunol 2019;337:42–47. DOI:10.1016/j.cellimm.2019.01.006
   PubMed Web of Science ®Google Scholar
• van Beek LF, de Gouw D, Eleveld MJ, et al. Adaptation of Bordetella pertussis to the respiratory tract. J Infect Dis 2018;217(12):1987–1996. DOI:10.1093/infdis/jiy125
   PubMed Web of Science ®Google Scholar
• Komatsu E, Yamaguchi F, Abe A, et al. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol CVI. 2010;17(5):807–812.
   PubMedGoogle Scholar
• Guiso N, Capiau C, Carletti G, et al. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine. 1999;17(19):2366–2376. DOI:10.1016/S0264-410X(99)00037-7
   PubMed Web of Science ®Google Scholar
• Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Br J Pharmacol 2020;177(16):3617–3624. DOI:10.1111/bph.15193
   PubMed Web of Science ®Google Scholar
• Poyntz HC, Jones A, Jauregui R, et al. Genetic regulation of antibody responsiveness to immunization in substrains of BALB/c mice. Immunol Cell Biol 2019;97(1):39–53. DOI:10.1111/imcb.12199
   PubMed Web of Science ®Google Scholar
• Mosley YC, Radder JE, HogenEsch H. Genetic variation in the magnitude and longevity of the IgG subclass response to a diphtheria-tetanus-acellular pertussis (DTaP) vaccine in mice. Vaccines (Basel). 2019;7(4).
   PubMed Web of Science ®Google Scholar
• Mosley YC, Radder JE, Berndt A, et al. Genome-Wide association mapping of the antibody response to diphtheria, tetanus and acellular pertussis vaccine in mice. J Infect Dis 2017;215(3):466–474.
   PubMed Web of Science ®Google Scholar
• Ying-Hua XU, Luo P, Wang LC. Development and validation of ELISA assays for determination of serum antibody against pertussis toxin, filamentous hemagglutinin, pertactin of Bordetella pertussis. Chin J Vaccine Immun; 2011.
   Google Scholar
• Commission CP. Pharmacopoeia of The People’s Republic of China. China Medicine Science Press; 2020.
   Google Scholar
• Knezevic I, Baca-Estrada M, Xing DK, et al. WHO working group meeting on standardization of acellular pertussis vaccines: potency assay Beijing, People’s Republic of China, 7-9 November 2007. Vaccine. 2008;26(32):3960–3968.
   PubMed Web of Science ®Google Scholar
• Gaines-Das R, Horiuchi Y, Zhang SM, et al. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines. Vaccine. 2009;27(49):6824–6832. DOI:10.1016/j.vaccine.2009.09.014
   PubMed Web of Science ®Google Scholar
• Xing D, Asokanathan C, Xu YH, et al. Relationship of immunogenicity to protective potency in acellular pertussis vaccines. Hum Vaccin Immunother. 2014;10(7):2066–2073. DOI:10.4161/hv.28765
   PubMed Web of Science ®Google Scholar
• Isomura S. Clinical studies on efficacy and safety of acellular pertussis vaccine. Tokai J Exp Clin Med 1988;13:39–43.
   PubMedGoogle Scholar
• Sato Y, Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Exp Clin Med 1988;13(Suppl):79–88.
   PubMedGoogle Scholar
• von Hunolstein C, Gomez Miguel MJ, Pezzella C, et al. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines. Pharmeuropa Bio. 2008;1:7–18.
   Google Scholar
• van der Ark A, van Straaten-van de Kappelle I, Olander RM, et al. The pertussis serological potency test. collaborative study to evaluate replacement of the mouse protection test. Biologicals. 2000;28(2):105–118.
   PubMed Web of Science ®Google Scholar
• Li SH, Xiao ZR, Liu BK. Establishment and adaptivity of pertussis serological potency test. Chin J Biologicals. 2009;22(11):1105–1109.
   Google Scholar
• Mohammadbagher D, Noofeli M, Karimi G. Comparative assessment of the whole-cell pertussis vaccine potency using serological and intracerebral mouse protection methods. Arch Razi Inst. 2019;74(2):103–109.
   PubMedGoogle Scholar
• van Der Ark A, Straaten-Van De Kappelle v, Hendriksen II, et al. Pertussis serological potency test as an alternative to the intracerebral mouse protection test: development, evaluation and validation. Altex. 1998;15(5):33–36.
   PubMedGoogle Scholar
• van der Ark A, van Straaten-van de Kappelle I, Hendriksen C, et al. Pertussis serological potency test as an alternatively to the intracerebral mouse protection test. Dev Biol Stand 1996;86:271–281.
   PubMedGoogle Scholar
• Hoonakker ME, Verhagen LM, van der Maas L, et al. Adaptive immune response to whole cell pertussis vaccine reflects vaccine quality: A possible complementation to the Pertussis Serological Potency test. Vaccine. 2016;34(37):4429–4436. DOI:10.1016/j.vaccine.2016.07.011
   PubMed Web of Science ®Google Scholar
• Yano A, Komatsu T, Ishibashi M, et al. Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy. Microbiol Immunol 2007;51(7):685–699. DOI:10.1111/j.1348-0421.2007.tb03957.x
   PubMed Web of Science ®Google Scholar
• Treger RS, Pope SD, Kong Y, et al. The lupus susceptibility locus Sgp3 encodes the suppressor of endogenous retrovirus expression SNERV. Immunity. 2019;50(2):334–347.e9. DOI:10.1016/j.immuni.2018.12.022
   PubMed Web of Science ®Google Scholar
• Ulland TK, Jain N, Hornick EE, et al. Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. Nat Commun. 2016;7:13180. DOI:10.1038/ncomms13180
   PubMed Web of Science ®Google Scholar
• Kaushansky A, Austin LS, Mikolajczak SA, et al. Susceptibility to Plasmodium yoelii preerythrocytic infection in BALB/c substrains is determined at the point of hepatocyte invasion. Infect Immun 2015;83(1):39–47. DOI:10.1128/IAI.02230-14
   PubMed Web of Science ®Google Scholar
• Farkas B, Boldizsar F, Tarjanyi O, et al. BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance. Arthritis Res Ther 2009;11(1):R21), DOI:10.1186/ar2613
   PubMed Web of Science ®Google Scholar
• Avila-Calderon ED, Lopez-Merino A, Jain N, et al. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice. Clin Dev Immunol 2012;2012:352493.
   PubMedGoogle Scholar